Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Rallybio (RLYB) Gains from Sales and Divestitures (2022)

Rallybio's Gains from Sales and Divestitures history spans 1 years, with the latest figure at $2000.0 for Q4 2022.

On a quarterly basis, Gains from Sales and Divestitures changed N/A to $2000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $2000.0, a N/A change, with the full-year FY2022 number at $2000.0, changed N/A from a year prior.
Gains from Sales and Divestitures hit $2000.0 in Q4 2022 for Rallybio.
Over the last five years, Gains from Sales and Divestitures for RLYB hit a ceiling of $2000.0 in Q4 2022 and a floor of $2000.0 in Q4 2022.